Fig. A.

Normalized expression data for the Affymetrix U133_Plus2 probeset with the highest intensity for STEP are shown for PFC (top) and associative striatum (bottom). No groups had a statistically significant difference from the control group in any probeset. Fig. B. Parvalbumin mRNA is significantly reduced in PFC from schizophrenia subjects as measured by RT-PCR (**p<0.01, ***p<0.0001). Fig. C. Top: Western blot using STEP KO mouse striatal lysates to validate the polyclonal STEP antibody used to measure human STEP protein. Bottom: Western blot probing with the same STEP antibody evaluating recombinant human STEP46, full-length STEP61, and a variant of STEP61 missing a 23 amino acid proline-rich juxtamembrane domain (PRJD). Table A. STEP mRNA levels in cortex: results for testing significance of fixed effects in mixed model. Table B. STEP61 protein in cortex: initial results for testing significance of fixed effects in the full mixed model, including all interactions between covariates and the CASE factor. Table C. STEP61 protein in cortex: results of multiple comparisons tests for pairwise differences amongst covariate-adjusted means. Table D. STEP61 protein in striatum: initial results for testing significance of fixed effects in the full mixed model, including all interactions between covariates and the CASE factor. Table E. STEP61 protein in striatum: results of multiple comparisons tests for pairwise differences amongst covariate-adjusted means. Table F. STEP46 protein in striatum: initial results for testing significance of fixed effects in the full mixed model, including all interactions between covariates and CASE factor. Table G. STEP46 protein in striatum: results of multiple comparisons tests for pairwise differences amongst covariate-adjusted means.
(DOCX)